JSPR — Jasper Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1788028 ·
Last close
$10.34
Market Cap
$344.06M
52W High
$72.60
52W Low
$9.25
ADV30
22,323
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 8,000,000 | 7,000 | -14,679,000 | -144,455,000 | 147,416,000 | 135,349,000 | 287,663,000 |
| Jun 2026 | 0 | — | -9,207,000 | -2,760,000 | 11,802,000 | 7,314,000 | 10,389,000 |
| Mar 2026 | 0 | — | -10,952,000 | -1,174,000 | 21,184,000 | 14,144,000 | 17,784,000 |
| Dec 2025 | 0 | — | -15,839,000 | -9,101,000 | 35,779,000 | 28,692,000 | 31,628,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-60,333,000
Investing CF
$80,000
Financing CF
$34,211,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.59
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-320,604,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-55,164,000
Pretax Income TTM
$-31,771,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -83,883,000 | -75,801,000 | 35,779,000 | 31,628,000 | 4,151,000 | -77,161,000 |
| Dec 2024 | 0 | -76,239,000 | -71,269,000 | 79,899,000 | 18,225,000 | 61,674,000 | -62,602,000 |
| Dec 2023 | 0 | -68,861,000 | -64,465,000 | 94,892,000 | 16,452,000 | 78,440,000 | -52,067,000 |
| Dec 2022 | 0 | -51,196,000 | -37,685,000 | 48,361,000 | 12,372,000 | 35,989,000 | -45,858,000 |
TTM Snapshot
Revenues TTM
$926,000
NetIncome TTM
$-31,771,000
OpCashFlow TTM
—
Assets (Latest)
$11,802,000
Forward EPS
$-2.56
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SLBT | SL Science Holding Ltd | $356.14M | $0.64 | — |
| CCCC | C4 Therapeutics, Inc. | $332.23M | $2.53 | — |
| XFOR | X4 Pharmaceuticals, Inc | $315.53M | $3.09 | — |
| ALEC | Alector, Inc. | $381.13M | $2.56 | — |
| TECX | Tectonic Therapeutic, Inc. | $392.55M | $20.08 | — |
News headlines (Yahoo Finance, 1h cache)
Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-16 13:00 · Yahoo
Jasper Therapeutics, Inc. Announces Results of the Offer to Purchase Relating to Its Warrants
2026-11-09 13:00 · Yahoo
Jasper Therapeutics Announces 1-for-30 Reverse Stock Split
2026-11-04 13:00 · Yahoo
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
2026-10-15 12:00 · Yahoo
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
2026-10-07 12:00 · Yahoo
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
2026-09-15 20:05 · Yahoo
Jasper Therapeutics beats Q2 expectations but shares fall after results
2026-08-17 12:30 · Yahoo
Jasper gets a lifeline in merger with immune drugmaker Kira
2026-07-17 11:54 · Yahoo
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7
2026-04-07 14:29 · Yahoo
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
2026-03-30 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.